Lifecycle
Announced
stage pending
Spin-off detail
CUMBERLAND PHARMACEUTICALS INC -> SpinCo
CPIX / n/a ยท detected 2026-03-09
Triage
Monitor
MONITOR
Confidence
37%
detection/extraction
Listing
n/a
distribution n/a
Extracted thesis
Shareholders of record can vote their shares by marking the enclosed proxy, signing and dating the proxy card and mailing it in the enclosed envelope.
Shareholders can also vote using the Internet or mobile device.
Kazimi Chairman and Chief Executive Officer 1 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD APRIL 21, 2026 The 2026 Annual Meeting of Shareholders of Cumberland Pharmaceuticals Inc., will be held on April 21, 2026, at 9:30 a.m.
Shareholders of record at the close of business on February 27, 2026 are entitled to receive notification and vote at the Annual Meeting and any adjournments or postponements of the meeting.
If you were a shareholder at the close of business on February 27, 2026, you are entitled to vote at the Annual Meeting.
We are furnishing our proxy materials to you under Securities and Exchange Commission rules that allow companies to deliver proxy materials to their shareholders on the Internet.
Risk flags
Estimated float is unavailable from current filing data.
risk
Source Links
3-Year Financials
Revenue by year
Operating income or ebit by year
Margin by year
Margin trend
Ownership and float
Total shares
Parent retained shares percent
Insider or management shares percent
Restricted or locked up shares
Estimated float percent
Assumption noteFloat estimate unavailable from filing text.
Management incentives
Management ownership percent
Equity comp alignment indicators["  Definitive Proxy Statement o   Definitive Additional Materials o   Soliciting Material Pursuant to §240.14a-12 CUMBERLAND PHARMACEUTICALS INC.", "The Company's named executive officers are listed in the \"compensation Discussion and Analysis\" section below and the Company has disclosed the compensation of the named executive officers pursuant to SEC rules.", "approve the compensation of Cumberland’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and narrative discussion."]
Parent to spinoff leadership migration